Introduction
Anaemia is a common feature of Chronic Kidney Disease (CKD) and when untreated is strongly associated with poor outcomes, resulting in increased hospitalisations and mortality. This chapter describes analyses of the UK Renal Registry (UKRR) data relating to the management of anaemia in dialysis patients during 2014.
The diagnosis and management of anaemia in chronic kidney disease and the standards to be achieved have been detailed in the Kidney Disease Improving Global Outcomes (KDIGO), Kidney Disease Outcomes Quality Initiative (KDOQI), European Best Practice Guidelines (EBPG) and UK Renal Association guidelines [1] [2] [3] [4] . The health economics of anaemia therapy using ESAs has also been subject to a National Institute of Clinical Excellence (NICE) systematic review which concluded that treating to a target haemoglobin (Hb) 110-120 g/L is cost effective in HD patients [5] . The NICE guidance was updated in June 2015 [6] but this will not have influenced the data reported in this chapter from 2014.
This chapter reports on the analyses of data items collected by the UKRR largely in the context of the 5th edition of the UK Renal Association's Anaemia in CKD guidelines and recommendations which was published at the end of 2010 [4] . Table 8 .1 lists the audit measures from these guidelines along with reasons for the exclusion of some of the measures.
The Proactive IV irOn Therapy in haemodiALysis patients (PIVOTAL) trial is a randomised control trial that has been recruiting in the UK since November 2013 in 40 renal centres (target 2,000 participants) to test the efficacy and safety of high-dose IV iron supplementation in incident haemodialysis patients. This is unlikely to have had a large impact on the centre level data presented in this chapter [7] .
Methods
Most of the analyses in this chapter use the incident or prevalent renal replacement therapy (RRT) cohorts for 2014. Some analyses use data from earlier years. Haemoglobin levels are given in g/L as the majority of UK laboratories have now switched to reporting using these units rather than g/dl.
The UKRR extracted quarterly data electronically from renal centres in England, Wales and Northern Ireland (E,W&NI) taking the latest available result from each quarter.
Data from Scotland were provided by the Scottish Renal Registry (SRR). For Q2 and Q4 the data provided were from May and November respectively due to the SRR's bi-annual census. For Q1 and Q3 the earliest available results in the quarter were provided. Data was provided for patients on treatment on 1st February, 1st May, 1st August and 1st November respectively for the four quarters. Therefore, for people who started treatment in the later part of each quarter, data was not available for the quarter of start. So, in order to improve completeness for the analysis of incident patients (see below), the cohort used for Scotland was patients starting treatment between 2nd November 2013 and 1st November 2014 inclusive and the definition of quarters was adjusted (e.g. for patients starting treatment from 2nd August 2014 up to 1st November 2014 the Hb data from Q4 was used).
For the analyses of Hb for incident patients, those patients commencing RRT on PD or HD were included whilst those receiving a pre-emptive transplant were excluded. Hb measurements from after starting dialysis but still within the same quarter of the year were used. Therefore, depending on when in the quarter a patient started RRT the Hb data could be from zero to 90 days later. Patients who died within the first 90 days on treatment were excluded. Results are also shown with the cohort subdivided into early and late presenters (date first seen by a nephrologist, 90 or more days and less than 90 days before starting dialysis respectively). For these analyses only centres with at least 75% completeness of presentation time data were included.
For the analyses of prevalent dialysis patients those patients receiving dialysis on 31st December 2014 were included if they had been on the same modality of dialysis in the same centre for at least three months. In order to improve completeness, the last available measurement for each patient from the last two quarters was used for Hb and from the last three quarters for ferritin.
The completeness of data items were analysed at both centre and country level. As in previous years, all patients were included in analyses but centres with less than 50% completeness were excluded from the caterpillar and funnel plots showing centre level results. Centres providing relevant data from less than 10 patients were also excluded from the plots. The number preceding the centre name in the caterpillar plots is the percentage of patients who have data missing.
Summary statistics including minimum, maximum, interquartile ranges (IQR), averages (mean and median) and standard deviations were calculated. The median values and the IQRs are shown using caterpillar plots. The percentages achieving standards were also calculated and these are displayed using caterpillar plots with the percentages meeting the targets and 95% confidence intervals (CIs) shown. Funnel plots show the distribution of the percentages meeting the targets and also whether any of the centres were significantly different from the average. Longitudinal analyses were performed to show overall changes in achievement of standards over time.
Erythropoietin data from the last quarter of 2014 were used to define which patients were receiving ESAs. Scotland was excluded from this analysis as data about ESAs was not included in its return. Each individual was defined as being on ESA if a drug type and/or a dose was present in the data. Centres reporting fewer than 60% of HD patients or fewer than 45% of PD patients being treated with ESAs were considered to have incomplete data and were excluded from further analysis. It is recognised that these exclusion criteria are relatively arbitrary but they are in part based upon the frequency distribution graph of centres' ESA use as it appears in the data. The percentage of patients on ESAs was calculated from these data and incomplete data returns risk seriously impacting on any conclusions drawn.
For analyses of ESA dose, values are presented as weekly erythropoietin dose. Doses of less than 150 IU/week (likely to be darbepoietin) were harmonised with erythropoietin data by multiplying by 200. No adjustments were made with respect to route of administration. Patients who were not receiving ESAs were not included in analyses of dose (rather than being included with dose = 0).
Until three years ago, UKRR annual reports only used the dose from the final quarter of the year. Now, starting with the cohort of patients receiving ESAs in the final quarter and having a dose value present for that quarter, any further dose values available from the earlier three quarters of the year were used (provided the patient was on the same treatment and receiving the same drug in those quarters). The average (mean) of the available values was then used in analyses rather than the dose in the final quarter.
The ESA data were collected electronically from renal IT systems but in contrast to laboratory linked variables the ESA data required manual data entry. The reliability depended upon the data source, whether the entry was linked to the prescription or whether the prescriptions were provided by the primary care physician. In the latter case, doses may not be as reliably updated as the link between data entry and prescription is indirect.
Results
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The Hb at the time of starting RRT gives the only indication of concordance with current anaemia management recommendations in the pre-dialysis (CKD 5 not yet on dialysis) group. The percentage of data returned and outcome Hb are listed in table 8.2. Results are not shown for London Guys as no Hb data was available. The median Hb of patients at the time of starting dialysis in the UK was 100 g/L. The median Hb when starting dialysis is shown in figure 8.1. The percentage of patients having a Hb 5100 g/L was again 50% after falling over the previous years from the 55% seen for the 2009 cohort. The percentage starting with a Hb 5100 g/L by centre is given in figure 8.2.
The variation between centres in the proportion of patients starting dialysis with Hb 5100 g/L remained high (27-89%). Using the centres that had provided the date of first presentation with good completeness, the Anaemia management in UK dialysis patients Gilg/Rao/Williams median Hb in the late presenters was 94 g/L with only 33% of patients having a Hb 5100 g/L compared with a median Hb of 101 g/L and 54% of patients having a Hb 5100 g/L in the early presenters. In both groups there was large variation between centres in the percentage of patients having a Hb 5100 g/L (9-70% in the late presenters and 30-90% in the early presenters). Median Hb of patients at the time of starting HD was 97 g/L (IQR 87-106 g/L) and in those starting PD it was 108 g/L (IQR 100-117 g/L). When starting dialysis, 43% of HD patients had a Hb 5100 g/L, compared with 75% of PD patients.
Incident dialysis patients from 2013 were followed for one year and the median haemoglobin (and percentage with a Hb 5100 g/L) of survivors on the same treatment at the same centre after a year was calculated for each quarter. Only patients who had Hb data for each of the four time points were included in this analysis. This was sub-analysed by modality and length of pre-RRT care (figures 8.3, 8.4) . Hb was higher in the second quarter on dialysis than during the quarter at start of dialysis reflecting the benefits of treatment administered. Over 75% of incident patients surviving to a year had Hb 5100 g/L regardless of the modality or the length of pre-RRT care.
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Anaemia management in prevalent dialysis patients
Haemoglobin in prevalent peritoneal dialysis patients
Overall, 83% of patients on PD had a Hb 5100 g/L (table 8. 
Relationship between Hb in incident and prevalent dialysis patients in 2014
The relationship between the percentage of incident and prevalent dialysis (HD and PD) patients with a Hb 5100 g/L is shown in figure 8.17. As expected, all centres had a higher percentage of prevalent patients achieving a Hb 5100 g/L than that for incident patients. Overall in Erythropoietin stimulating agents in prevalent haemodialysis patients
As shown in previous reports there was substantial variation in the average dose of ESA prescription used. who were receiving an ESA and had dose data available. There was no meaningful relationship in either figure.
It is known that not all patients treated with dialysis who have a Hb above 120 g/L are receiving ESA. It has been suggested that it may be inappropriate to include those patients not receiving ESA within the group not meeting this RA target. There are two reasons: firstly, the high Hb remains outside the control of the clinician, and secondly, the recent trials suggesting that it may be detrimental to achieve a high Hb in renal patients were based only upon patients treated with ESAs [8, 9] . Figures 8.29 and 8.30 show the percentages of HD and PD patients in each centre whose Hb lies above, within or below the RA guidelines of 100-120 g/L. These charts also show the proportion of patients with a Hb above the upper limit who were receiving, or were not receiving an ESA. These figures show that, in those centres for which useable ESA data was available, 23% of HD patients had a Hb .120 g/L and that most of these patients (78%) were on ESAs. For PD, 25% of patients had a Hb .120 g/L but only about half (49%) of these were on ESAs.
ESA prescription: age and modality associations
The proportion of patients on an ESA was higher for HD (87%) than PD (68%) and this difference was present and similar across all age groups (figure 8.31). The proportion of patients who had a Hb 5100 g/L without requiring ESA is shown (by age group and modality) in figure 8.32.
ESAs and time on renal replacement therapy
The percentage of patients on ESA by time on RRT and dialysis modality is shown in figure 8 .33. This is a cross-sectional analysis at the final quarter of 2014. Patients who had previously changed RRT modality were included in this analysis. The proportion of PD patients on ESA rises with duration of RRT from 65% after 3-12 months to 83% after 10 or more years. For at least the first 10 years on RRT, a greater percentage of HD patients were receiving ESA treatment than patients on PD.
Resistance to ESA therapy Figure 8 .34 shows the frequency distribution of weekly ESA dose adjusted for weight by treatment modality. RA guidelines define resistance to ESA therapy as 'failure to reach the target Hb level despite SC epoetin dose >300 IU/kg/week (450 IU/kg/week IV epoetin) or darbepoetin dose >1.5 mcg/kg/week'. For the purposes of this analysis the centres were restricted to those with good completeness for weight (over 75%) and ESA dose data (33 centres for HD and 20 centres for PD). As per the above definition and assuming that HD patients largely receive ESA intravenously and PD patients receive ESA subcutaneously, the prevalence of high doses of ESA was 1.0% (N = 76) and 1.9% (N = 9) for HD and PD patients respectively. For these patients the dose range for HD was 450-862 IU/kg/week and for PD 305-509 IU/kg/week. For patients on HD with high ESA doses, 47% (N = 36) had Hb ,100 g/L and 49% were within 100-120 g/L. For patients on PD with high ESA doses, 44% (N = 4) had a Hb ,100 g/L and the remaining 56% were within 100-120 g/L. The percentage of patients with ESA resistance, defined as those failing to reach Hb 5100 g/L despite a high dose of ESA, were 0.5% for HD and 0.9% for PD.
Success with guideline compliance
Compliance with current minimum standards by year (1998 to 2014) is shown in figure 8 .35 for prevalent patients (by treatment modality). Figure 8 .36 shows the percentage of anaemic patients (Hb ,100 g/L) receiving an ESA. A minority of patients with Hb ,100 g/L were not receiving ESA therapy.
Across the age groups this was between 7-13% for HD patients and 4-19% for PD patients. Table 8 .6 shows that the percentage of all patients treated with an ESA and having Hb .120 g/L ranged between 5-38% for HD and between 0-27% for PD. For HD, there was a small percentage of patients having ferritin levels ,100 mg/L and being on an ESA (0-8%). The percentages were somewhat higher for PD (0-20%). Table 8 .7 shows the percentage completeness for drug type, dose, route and frequency of administration for centres reporting ESA data. The completeness was generally good for drug type and dose but patchy for frequency and route of administration. Leeds  429  100  100  100  99  40  100  100  100  100  Leic  817  100  100  0  0  90  100  100  0  0  Middlbr  229  100  100  0  0  9  100  100  0  0  Newc  178  100  100  0  0  Norwch  275  100  100  99  100  21  100  100  90  100  Nottm  295  100  99  0  0  51  100  49  0  0  Oxford  392  100  99  0  0  61  100  93  0  0  Prestn  435  100  19  0  0  35  100  0  0  0  Redng  231  100  100  0  0  Salford  256  100  100  98  0  Sheff  490  100  92  0  0  25  100  100  0  0  Shrew  156  100  100  98  97  16  100  100  100  100  Sthend  102  100  95  0  0  11  100  82  0  0  Sund  180  100  100  0  0  8  100  100  0  0  Wolve  235  100  100  99  100  47  100  100  100  100  York  111  100  100  100  98  12  100  92  100  100  N Ireland  Antrim  102  100  100  100  100  11  100  100  100  100  Belfast  177  100  100  100  100  11  100  100  100  100  Newry  77  100  100  97  100  12  100  100  100  100  Ulster  91  100  100  100  100  4  100  100  100  100  West NI  94  100  100  100  100  10  100  100  100  100  Wales  Bangor  54  100  0  0  0  Swanse  269  100  96  96  99  28  100  96  96  100  England  9,063  100  93  40  29  928  100  89  38  32  N Ireland  541  100  100  100  100  48  100  100  100  100  Wales  323  100  80  80  82  28  100  96  96 
